Contact

Independent information resource Evidence · Safety · Uncertainty Koru Vale An independent resource on ibogaine and depression research. Home About Services Treatment Overview Safety & Screening Research Landscape Contact Investigational treatment context Ibogaine Treatment For Depression Ibogaine is being studied as a possible rapid-acting option for severe, treatment-resistant depression. The interest is real; so are the limits of the evidence and the safety concerns. Koru Vale · Independent resource Updated August 10, 2026 Adult information guide Ibogaine is a naturally occurring psychoactive compound derived from the iboga plant. Its metabolite, noribogaine, is thought to contribute to longer-lasting effects. In the depression context, ibogaine is being studied for treatment-resistant depression, often alongside PTSD, anxiety, and traumatic brain injury—not as routine first-line depression care. Interest has grown because the treatment is sometimes framed as a rapid, single-session option for people whose depression has not responded to standard approaches. But ibogaine is not an approved depression medicine in the United States. It remains Schedule I federally, as described in the DEA’s drug scheduling framework , and general medical use is still outside standard care. “Ibogaine treatment” usually means a medically supervised protocol with cardiac screening and monitoring, often in research settings or offshore clinics. It should not be understood as casual psychedelic use. The compound’s history, chemistry, and plant origin are outlined in the ibogaine reference overview , but a reference entry does not establish clinical effectiveness. The strongest human findings for depression come from a small open-label Stanford study in veterans with traumatic brain injury. That study reported large short-term changes in depression, PTSD, and anxiety symptoms. Stanford’s own account of how ibogaine may inspire new treatments for addiction and depression reflects why t

Contact

A note on reaching us